"He's the CEO of Cytodyn Therapeutics, which is a clinical stage biotech company that's advancing a first-in-class monoclonal antibody that targets a chemokine receptor, one of the chemokine receptors called CCR5, which is one of the master regulators of immune cell trafficking."

Cytodyn Therapeutics? I didn't see where Dr Lalezari corrected him.